Skip to content

Long-term neuropsychological outcome in pediatric anti-NMDAR encephalitis

Long-term neuropsychological outcome in pediatric anti-NMDAR encephalitis - Outcome in pediatric NMDARE

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON42623
Enrollment
50
Registered
2015-10-13
Start date
2015-04-14
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hersenontsteking NMDA receptor encefalitis

Interventions

None listed

Sponsors

Neurologie
Lead Sponsor

Eligibility

Age
2 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Cross-sectional part: patients who have had anti-NMDA receptor encephalitis before January 2015, who were age 18 or younger at disease onset and currently age 4 or older. - Prospective parts: patients who have had anti-NMDA receptor encephalitis after January 2015, who were age 3.5 to 18 at disease onset - Patient was diagnosed in Dutch tertiary pediatric hospitals, or antibody testing had been performed in our center. - Patient speaks Dutch or English.

Exclusion criteria

Exclusion criteria: - Age over 18 years at disease onset, or current age younger than 4 - Patient or legal representative is withholding informed consent - Patient or legal representative objects after initial informed consent (see paragraph 8.4)

Design outcomes

Primary

MeasureTime frame
Identification of clusters of impairment in cognition and behavior after pediatric anti-NMDAR encephalitis

Secondary

MeasureTime frame
- Identification of risk factors affecting functional outcome - Analyzing progression or remission over time - Analyzing the phenomenom of 'growing into deficit'

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)